Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

World AIDS Day 2017: Enabling broad access to best-in-class HIV treatment – Best practice for originators

For World AIDS Day 2017, Clinton Health Access Initiative and the Access to Medicine Foundation have co-authored a paper describing best-practice licencing models that originator companies can employ to enable broad access to ARVs. The paper also explores a set of broader supportive activities that help ensure licences have maximum impact on access.

Date

01 December 2017

Download the paper

Years of experience show that licensing is highly effective for ensuring that many more people in low- and middle-income countries, particularly in sub-Saharan Africa, can access life-saving medicines for HIV.

This paper describes the ‘best practice’ licensing models that originator companies should employ to enable broad access, including: signing licences as early as possible; broadening the geographic scope of licences; and, limiting the use of licence terms that restrict generic medicine manufacturers. It further explores how originator companies can go beyond licensing and engage in broader supportive initiatives that help ensure their licences have maximum impact. This includes: registering products widely and quickly; maintaining branded supply at affordable prices; generating clinical data to address needs in low and middle income countries; and, engaging when requested in technology transfers.

These activities should be underpinned with strong governance structures for access to ensure an integrated approach that is successful for increasing access to HIV treatment. Importantly, these best practices have the potential to serve as models to also broaden access to key medicines targeting other high-burden diseases in low and middle income countries.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved